U.S. stocks rose on Wednesday as investors digested the Federal Reserve's December meeting minutes.
Stocks rose on Tuesday, the first trading day of 2017, but closed off their session highs as oil prices gave back initial gains.
The New York Times looks back at the year that was to toast and roast the year's deal makers and look ahead to what may come next.
The bull market enters the new year with a bit more spring in its step, but 2017 is not without its risks.
ConAgra, Rite Aid, and Hershey stocks are making headlines this Thursday morning before the opening bell.
Fred's Pharmacy said it signed an agreement with Walgreens and Rite Aid to purchase stores and certain assets for $950 million in cash.
Jefferies on Monday downgraded CVS to hold from buy, predicting weak earnings in 2017 as the firm struggles with market share losses.
The legendary investing club, which started in 1983, gives their take on stocks today.
There's a change in the market wind, which explains why stocks keep on rallying.
Experts scramble to factor Trump's corporate tax plans into the 2017 earnings equation.
Here's what investors should have done instead of cherry-picking key sectors to buy and sell.
The market has floated to new highs based on the belief that the United States will have a period of stronger economic growth.
Media mogul Rupert Murdoch was among investors who piled into blood-testing start-up Theranos, the WSJ reported.
Stocks keep flirting with record highs, but is now a good time for retail investors to take cash off the table?
This is the third lawsuit filed by investors against the company since Oct. 10, but the first to seek class-action status, the report said.
December is traditionally a bullish month, but are we setting ourselves up for a disappointment? Is it all too far too fast?
Some of the names on the move ahead of the open.
Elizabeth Holmes wants to change health care as we know it, venture capitalist and Theranos investor Tim Draper says.
Pill-packing robots are working behind the scenes at pharmacies as prescription volume has boomed. The No. 1 goal is reducing errors to zero.
Jim Cramer got to the bottom of why CVS’s stock has dropped so quickly, and why he's got it in the penalty box.